~~<i id='BD82C30184'><strike id='BD82C30184'><tt id='BD82C30184'><pre id='BD82C30184'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：fashion 2025-09-27 15:48:27 Page View：45824

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： WATCH: Why do our ears pop?
Next article： Sports medicine is finally prioritizing gender equality

knowledge

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Food makers tried to stack nutrition panel with preferred experts

There’sapanelof20nutritionexpertsthathasoutsizedinfluenceontheAmericandiet—andthefoodindustryhaswork

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

FDA proposes changes to key medical devices approval pathway

Lastweek,theFDAreleasedatrioofguidelinesclarifyingthewaytheyplantoevaluatedevicesthatgothroughthe510